Biogen and Ionis Pharmaceuticals’ Spinraza could be on the US market within weeks after a phase 3 trial in the rare neuromuscular disorder, spinal muscular atrophy, met its goal. The ...

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted Biogen’s applications for a higher dose regimen of spinal muscular atrophy (SMA) treatment Spinraza ...

Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...

If you need financial support to pay for Spinraza or help with understanding your insurance coverage, help is available. For example: Biogen, the manufacturer of Spinraza, has a financial assistan ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Biogen, Inc. is a biopharmaceutical company ... TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM ...

Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). Please click here for Important Safety Information and ...